Funds Holding Forest Laboratories, Inc.

Also showing items for ETFS Holding Forest Laboratories, Inc.

 
Funds Holding Forest Laboratories, Inc. top ^
  • Holdings: Merck & Co Inc, Amgen Inc, UnitedHealth Group Inc, Forest Laboratories, Inc., Roche Holding AG
  • Category: Health
  • Morningstar Rating: 4 Stars
Sign-up for vghcx investment picks
  • Holdings: Merck & Co Inc, Amgen Inc, UnitedHealth Group Inc, Forest Laboratories, Inc., Roche Holding AG
  • Category: Health
  • Morningstar Rating: 4 Stars
Sign-up for vghax investment picks
  • Holdings: Forest Laboratories, Inc., Southwest Airlines Co, ConAgra Foods, Inc., Noble Energy Inc, Dover Corporation
  • Category: Mid-Cap Value
  • Morningstar Rating: 4 Stars
Sign-up for dhmyx investment picks
  • Holdings: Forest Laboratories, Inc., Southwest Airlines Co, ConAgra Foods, Inc., Noble Energy Inc, Dover Corporation
  • Category: Mid-Cap Value
  • Morningstar Rating: 3 Stars
Sign-up for dhmax investment picks
  • Holdings: Forest Laboratories, Inc., Southwest Airlines Co, ConAgra Foods, Inc., Noble Energy Inc, Dover Corporation
  • Category: Mid-Cap Value
  • Morningstar Rating: 4 Stars
Sign-up for dhmcx investment picks
  • Holdings: Forest Laboratories, Inc., Southwest Airlines Co, ConAgra Foods, Inc., Noble Energy Inc, Dover Corporation
  • Category: Mid-Cap Value
  • Morningstar Rating: 4 Stars
Sign-up for dhmix investment picks
  • Holdings: Forest Laboratories, Inc., Southwest Airlines Co, ConAgra Foods, Inc., Noble Energy Inc, Dover Corporation
  • Category: Mid-Cap Value
  • Morningstar Rating: 4 Stars
Sign-up for dhmax.lw investment picks
  • Holdings: Merck & Co Inc, Amgen Inc, UnitedHealth Group Inc, Forest Laboratories, Inc., Roche Holding AG
  • Category: Health
  • Morningstar Rating: 4 Stars
Sign-up for VGHAX investment picks

 
Stock Quotes for Forest Laboratories, Inc. top ^
  • Industry: Drug Manufacturers - Specialty & Generic
  • Sector: Healthcare
  • Stock Style: Mid Growth
  • Stock Type: Aggressive Growth
  • Morningstar Rating: 3 Stars
Sign-up for frx investment picks
  • Industry: Drug Manufacturers - Specialty & Generic
  • Sector: Healthcare
  • Stock Style: Mid Growth
  • Stock Type: Aggressive Growth
  • Morningstar Rating: 3 Stars
Sign-up for frx investment picks

 
News Articles for Forest Laboratories, Inc. top ^
2013/4/2
Forest Laboratories, Inc. (NYSE: FRX) , an international manufacturer and marketer of pharmaceutical products, will release its Fiscal 2013 Fourth Quarter financial results before the U.S. stock market opens on Tuesday, April 23, 2013.
Sign-up for Forest Laboratories, Inc. Sets Date and Conference Call for Fiscal 2013 Fourth Quarter Earnings investment picks
2013/4/16
Almirall and Forest Laboratories Announce Positive Results of a Phase III Study for Aclidinium and Formoterol Combination in COPD Canada NewsWire BARCELONA AND NEW YORK, April 16, 2013 /CNW/ - Almirall, S.A. (ALM:MC) and Forest Laboratories, Inc. (NYSE:FRX) today announced positive topline results from a six month pivotal phase III clinical trial evaluating the efficacy and safety of fixed dose combinations of aclidinium bromide (LAMA) and formoterol fumarate (LABA) delivered by Almirall's inhaler Genuair ®  (Pressair™ in the USA). Both combinations of aclidinium/formoterol (400/6mcg and 400/12mcg twice a day) demonstrated statistically significant improvements in the co-primary endpoints of change from baseline in morning predose trough FEV1 versus formoterol 12mcg and in FEV1 at 1 hour post-dose versus aclidinium 400mcg both at week 24 (p<0.01 and p≤0.0001, respectively). In addition, both combinations of aclidinium/formoterol
Sign-up for Almirall and Forest Laboratories Announce Positive Results of a Phase III Study for Aclidinium and Formoterol Combination in COPD investment picks
2013/4/16
Almirall, S.A. (ALM:MC) and Forest Laboratories, Inc. (NYSE:FRX) today announced positive topline results from a six month pivotal phase III clinical trial evaluating the efficacy and safety of fixed dose combinations of aclidinium bromide, (LAMA) and formoterol fumarate (LABA) delivered by Almirall’s inhaler Genuair ® (Pressair™ in the USA). Both combinations of aclidinium/formoterol (400/6mcg and 400/12mcg given twice a day) demonstrated statistically significant improvements in the co-primary endpoints of change from baseline in morning predose trough FEV1 versus formoterol 12mcg and in FEV1 at 1 hour post-dose versus aclidinium 400mcg at week 24 (p<0.01 and p≤0.0001, respectively). In addition, both combinations of aclidinium/formoterol (400/6mcg and 400/12mcg) provided statistically significant improvements versus placebo in the above two variables (both
Sign-up for Almirall and Forest Laboratories Announce Positive Phase III Study Results for Aclidinium and Formoterol Combination in COPD investment picks
2013/4/23
Forest Laboratories, Inc. (NYSE: FRX) , an international pharmaceutical manufacturer and marketer, today announced that reported diluted earnings per share equaled $0.17 in the fourth quarter of fiscal 2013.
Sign-up for Forest Laboratories, Inc. Reports Fiscal Year Fourth Quarter 2013 Earnings Per Share of $0.17 Including $0.08 Per Share of Acquisition Amortization investment picks
2013/5/2
Almirall and Forest Laboratories Announce Positive Results for the Second Phase III Study for Aclidinium and Formoterol Combination in COPD Canada NewsWire BARCELONA and NEW YORK, May 2, 2013 /CNW/ - Almirall, S.A. (ALM:MC) and Forest Laboratories, Inc. (NYSE:FRX) today announced positive topline results from AUGMENT/COPD, the second six-month pivotal phase III clinical trial evaluating the efficacy and safety of investigational fixed dose combinations of aclidinium bromide (LAMA) and formoterol fumarate (LABA) for the treatment of Chronic Obstructive Pulmonary Disease (COPD), delivered in the Pressair™inhaler (Genuair ® outside the USA). The 400/12mcg combination of aclidinium/formoterol given twice daily demonstrated statistically significant improvements in change from baseline for the co-primary endpoints of Forced Expiratory Volume (FEV1) at 1 hour post-dose versus aclidinium 400mcg (p<0.0001), and morning predose trough FEV1
Sign-up for Almirall and Forest Laboratories Announce Positive Results for the Second Phase III Study for Aclidinium and Formoterol Combination in COPD investment picks
2013/5/1
Forest Laboratories, Inc. (NYSE:FRX) and Almirall, S.A. (ALM:MC) today announced positive topline results from AUGMENT COPD, the second six-month pivotal phase III clinical trial evaluating the efficacy and safety of investigational fixed dose combinations of aclidinium bromide (LAMA) and formoterol fumarate (LABA), delivered in the Pressair ® (Genuair ® outside the USA) inhaler.
Sign-up for Forest Laboratories and Almirall Announce Positive Results for the Second Phase III Study for Aclidinium and Formoterol combination in COPD investment picks
2013/5/9
Trevena Inc., (Trevena) a clinical stage pharmaceutical company and the leader in the discovery and development of G-protein coupled receptors (GPCR) biased ligands, and Forest Laboratories Holding Limited (Forest), a subsidiary of Forest Laboratories, Inc. (NYSE:FRX) , an international pharmaceutical company, announced today that they have entered into a collaborative licensing option agreement for the development of TRV027, an AT1R biased-ligand that recently completed Phase 2a clinical trials.
Sign-up for Trevena Inc. and Forest Laboratories Announce a Collaborative Agreement for Development of TRV027 for the Treatment of Acute Heart Failure investment picks
2013/5/9
Forest Laboratories leads Trevena's $60 Million Series C Funding Round; All existing investors to also participate KING OF PRUSSIA, Pa.
Sign-up for Trevena, Inc. and Forest Laboratories Announce a Collaborative Agreement For Development of TRV027 for the Treatment of Acute Heart Failure investment picks
2013/5/16
Forest Laboratories, Inc. (NYSE: FRX) , today announced it will be presenting data on two late-stage development products, cariprazine and levomilnacipran, at the American Psychiatric Association (APA) annual meeting scheduled May 18-22, 2013, in San Francisco, CA.
Sign-up for Forest Laboratories, Inc. to Present Data from Cariprazine and Levomilnacipran Phase 3 Trials at American Psychiatric Association Annual Meeting investment picks

Start Premium Trial Register For Free

P F Fund Financial Data (13,000+ funds)
P F Stock Financial Data (7,000+ stocks)
P F Stock and Fund Screeners (basic)
P F Investing Articles and Market Commentary
P F Articles Archive (>30 days)
P F Discuss (dozens of stock, fund, bond, and general bulletin boards)
P F Portfolio Manager (basic)
P F Morningstar Investment Classroom
P F Morningstar Investing Classroom Rewards (earn as you learn and redeem for Morningstar merchandise)
P   Morningstar Fund Analyst Reports (full research on 2,000 funds and ETFs)
P   Morningstar Stock Analyst Reports (full research on 2,000 stocks)
P   Morningstar Stock and Fund Stewardship Grades
P   Portfolio Manager (advanced with 10 x-ray analyses, including guidance)
P   Portfolio Monitor (monthly and on-demand personalized portfolio statements)
P   Morningstar Proprietary Stock Information (stock star ratings, buy/sell prices, economic moat ratings, and more)
P   Morningstar Stock and Fund Favorites & Red Flags eNewsletters
P   Premium Stock and Fund Screeners (advanced with nearly infinite ways to find the best securities for you)
P   Discounts on Morningstar newsletters, books, seminars, and more

Sign-up to Morningstar


Basic Access

Articles and Videos
Morningstar video reports, articles, data, and tools. Dig into our lineup of e-newsletters and investing classroom courses outlining sensible strategies for maximizing your investments.
Morningstar Discuss
Follow the buzz on individual stocks or fund families. Plus, read the latest posts from Morningstar members and analysts.
Portfolio Manager
Track your investments and watch lists with our Portfolio Manager. Customize your view with our comprehensive stock, fund, and ETF data.

Access these features and more when you sign up for Free Membership.
Join Morningstar today. It's Free.

Unlimited Access

Analyst Research
Gather in-depth, actionable insight on over 3,700 stock and mutual funds covered by Morningstar analysts. View our mutual fund Analyst Reports favored by professionals, savvy experienced investors, and new investors researching options for retirement savings, college plans, or other investment needs.
Portfolio X-Ray®
Ensure your portfolio is positioned exactly how you want with Morningstar's X-Ray Interpreter and Stock Intersection tools. A Barron's "Best of the Web" award winner for five years running, X-Ray Interpreter goes under the hood of your portfolio to provide a useful allocation, sector, and geographic analysis. And you can discover how much of a stock you really own, individually and through mutual funds, with Stock Intersection.
Investment Picks
Find new 5-star stocks (greatly undervalued companies) to consider daily. Our 5-star stock rating is a proven winner, consistently beating benchmarks like the S&P 500. Plus, browse our Fund Analyst Picks and Stewardship Grades to find shareholder-friendly mutual funds that are poised for outperformance.
Portfolio Monitor
Get a clear view of your investments with personalized reports about your portfolio. Receive monthly statements and generate reports on-demand to help you stay on track to meet your investment goals.

Access these features and more when you sign up for Premium Membership.
Start your free 14-day trial today online
Your subscription may be tax deductible. Please contact your tax advisor.

Funds Holding Forest Laboratories, Inc.
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Title |  Date |  Author |  Collection |  Interest |  Popularity Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry |  Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry

Previous: Funds Holding Ford Otomotiv Sanayi As  |  Next: Funds Holding Forestar Group, Inc.